Surufatinib
Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours.
Overview
Surufatinib (Sulanda) was discovered and developed by HUTCHMED in Shanghai. The NMPA approved it in December 2020 for unresectable locally advanced or metastatic, well-differentiated, non-pancreatic neuroendocrine tumours (SANET-ep trial) and in June 2021 for pancreatic neuroendocrine tumours (SANET-p trial). A US application was withdrawn in 2022 after the FDA asked for a multi-regional trial.
Blocks the VEGF and FGF receptors that build tumour blood vessels and the CSF1 receptor on tumour-associated macrophages, cutting the tumour's blood supply and its immune shelter at once. Connects to VEGF / VEGFR and CSF1R.
1.Surufatinib slips into a pocket on VEGF / VEGFR.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| CN | 2020 | Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021 |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Surufatinib" OR ABSTRACT:"Surufatinib" OR TITLE:"HMPL-012" OR ABSTRACT:"HMPL-012" OR TITLE:"sulfatinib" OR ABSTRACT:"sulfatinib" OR TITLE:"Sulanda" OR ABSTRACT:"Sulanda") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Surufatinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentVorolanib
Shares VEGF / VEGFR, Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentGumarontinib
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentLinperlisib
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentFlumatinib
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentIruplinalkib
Shares Small-molecule kinase inhibitors and the tags china, nmpa-approved.
- TreatmentBenmelstobart
Shares the tags china, nmpa-approved.
- TreatmentH101 oncolytic adenovirus
Shares the tags china, nmpa-approved.
- TreatmentInetetamab
Shares the tags china, nmpa-approved.